Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine how safe and effective subconjunctival
injections of CGC-11047 are in subjects with wet age related macular degeneration at two
different dosing intervals.